Background/Aims: The optimal timing for discontinuing oral antiviral therapy in patients with HBeAg-positive chronic hepatitis B (CHB) is unclear. The aim of our study was to investigate sustained remission after stopping antiviral therapy in patients with HBeAg-positive CHB. Methods: We analyzed the medical records of 58 patients who were HBeAg-positive and had discontinued antiviral therapy. Antiviral therapy was discontinued after HBeAg seroconversion and HBV DNA negativity for 6-12 months with consolidation therapy. Virologic relapse was defined as an increase in serum HBV DNA >2,000 IU/mL. Results: No difference was observed between the virologic non-relapse and virologic relapse groups in baseline HBV DNA level (p=0.441) or duration of seroconversion (p=0.070). Time-to-undetectable HBV DNA during treatment was shorter in the virologic non-relapse group (29 patients) compared to the relapse group (29 patients) (4.9±2.6 vs. 13.2±12.7 months; p<0.01). Cumulative relapse rates were 12.7 in month 3, 32.7 in month 6, 47.3 in month 12, and 52.7% in month 18. We determined by multivariate analysis that the consolidation period (≥18 months, p=0.020) and early virologic response (HBV DNA <20 IU/mL) at six months during antiviral therapy (p=0.017) were significant predictors for sustained remission. Conclusions: A consolidation period of at least 18 months and early virological response at six months during antiviral therapy were associated with sustained remission in patients with HBeAg-positive CHB after treatment. (Korean J Gastroenterol 2016;67:28-34) 
INTRODUCTION
HBV is an important contributor to liver disease, and chronic HBV infection can cause cirrhosis and hepatocellular carcinoma (HCC).
1 Antiviral therapy with nucleos(t)ides (NAs) is ef-fective in suppressing viral replication to normalize liver enzymes in patients with chronic HBV infection. The aim of this study was to investigate the factors predicting sustained remission after stopping antiviral therapy in patients with HBeAg-positive CHB.
SUBJECTS AND METHODS

Patients
We analyzed the medical records of patients who were
HBeAg-positive and had discontinued antiviral therapy from 
Statistics
Statistical analysis was performed using SPSS (version 14.0; SPSS, Inc., Chicago, IL, USA). Continuous variables were expressed as means with standard deviation or medians with range, and categorical variables were expressed as a proportion. Student's t-test and Mann-Whitney U-test or χ 2 test and Fisher's exact test were used to make comparisons between the sustained remission and relapse groups.
The cumulative relapse rate was calculated by the
